Details

Autor(en) / Beteiligte

• Bruni, Luca, MD
• Luisi, Stefano, MD, PhD
• Ferretti, Caterina, MD
• Janneau, Jean-Louis, MSc
• Quadrifoglio, Mariachiara, MD
• Richon, Sophie, MSc
• Dangles-Marie, Virginie, DVM, PhD
• Bellet, Dominique, MD, PhD
• Petraglia, Felice, MD

Titel

Changes in the maternal serum concentration of proearly placenta insulin-like growth factor peptides in normal vs abnormal pregnancy

Ist Teil von

• American journal of obstetrics and gynecology, 2007-12, Vol.197 (6), p.606.e1-606.e4

Ort / Verlag

Philadelphia, PA: Mosby, Inc

Erscheinungsjahr

2007

Quelle

ScienceDirect Pay Per View(PPV) Titles

Beschreibungen/Notizen

• Objective The objective of the study was to evaluate maternal serum pro–early placenta insulin like (proEPIL) levels during normal and pathologic pregnancy by using a newly developed enzyme-linked immunosorbent assay, based on a monoclonal antibody designated EPIL15 and directed to the pro-EPIL C-chain 98-108 region. Study Design In a group of healthy pregnant women (n = 22), proEPIL peptide serum levels were measured longitudinally throughout gestation (8-12, 20-24, and 30-34 weeks). Serum proEPIL levels were measured in women with preterm labor (n = 24), intrauterine growth restriction (n = 27), and preeclampsia (n = 12). Results In healthy pregnant women, a significant rise of serum pro-EPIL levels (mean ± SEM) was observed during the third trimester of gestation (30.97 ± 2.978 ng/mL; P < .01), with the highest serum levels at 30-34 weeks’ gestation ( P < .001). Serum proEPIL levels were found elevated in women with intrauterine growth restriction (107.4 ± 12.99 ng/mL), preeclampsia (104.8 ± 36.20 ng/mL), or preterm labor (183.8 ± 36.42 ng/mL) in comparison with levels observed in healthy pregnant women ( P < .001). Conclusion These results showed that proEPIL secretion increases in the last trimester during normal pregnancy and is highly secreted in women with pathologic conditions.